Status:
UNKNOWN
Liver Stiffness Measurement (LSM) in Predicting Progress of Liver Fibrosis After TACE for Hepatocellular Carcinoma
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Hepatocellular Carcinoma
Liver Failure
Eligibility:
All Genders
18-80 years
Brief Summary
Objective: To evaluate the efficacy of preoperative liver stiffness measurement(LSM) by FibroScan in predicting the progress of liver fibrosis and prognosis after transcatheter arterial chemoembolizat...
Eligibility Criteria
Inclusion
- age：18-80
- HCC diagnosed by pathologist or physician according to Guidelines
- Chronic Hepatitis B (CHB) background
- receive at least 1 TACE
- volunteer to join the research
Exclusion
- massive lesion with insufficient liver left for LSM examination
- associated with other liver diseases: Chronic Hepatitis C(CHC),Autoimmune Hepatitis(AIH),Wilson's disease.
- severe obesity(BMI\>28)
- pregnancy
- other inappropriate situation defined by investigators.
Key Trial Info
Start Date :
June 25 2018
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT03285867
Start Date
June 25 2018
End Date
December 1 2021
Last Update
April 30 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.